[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339967-105":59,"doc-detail-339967-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","crisprcas-mediated-knockdown-of-pd-l1-and-kras-in-lung-cancer-cells","CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells","","Cancer cells evade host immune surveillance through multiple mechanisms, including PD-L1/PD-1 signaling. PD-L1 is a transmembrane protein expressed on many cell types and can inhibit activated T-cell responses via PD-1, particularly in KRAS-mutated malignancies. This study applies CRISPR/Cas9 to knock down PD-L1 and KRAS in A549 and H1975 lung adenocarcinoma cells, validating PD-L1 loss by qPCR and lymphocyte coculture. Dual suppression slowed G0/G1 cell-cycle progression, reduced migration, increased chemotherapy sensitivity, and triggered apoptosis, also decreasing viability and drug resistance of native cancer cells exposed to conditioned medium, supporting a potential therapeutic strategy for lung cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/crisprcas-mediated-knockdown-of-pd-l1-and-kras-in-lung-cancer-cells/339967/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/crisprcas-mediated-knockdown-of-pd-l1-and-kras-in-lung-cancer-cells/339967.png","ImageObject",300,407,{"name":92,"@type":93},"Theodore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How were PD-L1 and KRAS knocked down in lung cancer cells?","Question",{"text":112,"@type":113},"The study used the CRISPR/Cas9 system to knock down PD-L1 and KRAS in A549 and H1975 lung adenocarcinoma cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was PD-L1 knockdown validated experimentally?",{"text":117,"@type":113},"PD-L1 knockdown was validated by qPCR and by coculture with lymphocytes.",{"name":119,"@type":110,"acceptedAnswer":120},"What effects did dual PD-L1 and KRAS silencing have on cancer cell behavior?",{"text":121,"@type":113},"Dual suppression slowed the cell cycle in G0/G1, reduced migration, increased chemotherapy sensitivity, and triggered apoptosis of cancer cells, with conditioned medium also reducing viability and drug resistance of native cancer cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339967,1790181568,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Article  \nCRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells  \nSummer A. Abounar 1, Nefertiti A. El-Nikhely 1,2, *, Kati Turkowski 3, Rajkumar Savai 3 and Hesham Saeed 1  \nCitation: Abounar, S.A.; El-Nikhely, N.A.; Turkowski, K.; Savai, R.; Saeed, H. CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells. Int. J. Mol. Sci. 2024, 25, 9086. [https://doi.org/](https://doi.org/)[ ](https://doi.org/)[10.3390/ijms25169086](10.3390/ijms25169086)  \nAcademic Editor: Cecilia Garofalo  \nReceived: 7 June 2024  \nRevised: 23 July 2024  \nAccepted: 2 August 2024  \nPublished: 22 August 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \n1 Department of Biotechnology, Institute of Graduate Studies and Research, Alexandria University, Alexandria 21526, Egypt; [summer.ashraf@alexu.edu.eg](summer.ashraf@alexu.edu.eg) (S.A.A.); [hesham25166@alexu.edu.eg](hesham25166@alexu.edu.eg) (H.S.)  \n2 Program of Molecular Biotechnology, Faculty of Advanced Basic Sciences, Alamein International University, New Alamein City, Marsa Matrouh 5060310, Egypt  \n3 Lung Microenvironmental Niche in Cancerogenesis, Institute for Lung Health (ILH), Justus Liebig University, 35390 Giessen, Germany  \n* Correspondence: [igsr.nelnikhely@alexu.edu.eg](igsr.nelnikhely@alexu.edu.eg)  \nAbstract: Cancer cells can escape death and surveillance by the host immune system in various ways. Programmed cell death ligand 1 (PD-L1) is a transmembrane protein that is expressed by most cell types, including cancer cells, and can provide an inhibitory signal to its receptor PD-1, which is expressed on the surface of activated T cells, impairing the immune response. PD-L1/PD-1-mediated immune evasion is observed in several KRAS-mutated cancers. In the current study, we used the CRISPR/Cas9 system to knock down PD-L1 and KRAS in adenocarcinoma lung cells (A549 and H1975) . Knockdown of PD-L1 was validated by qPCR and coculture with lymphocytes. The cells were functionally analyzed for cell cycle, migration and apoptosis. In addition, the effects of PD-L1 and KRAS downregulation on chemotherapy sensitivity and expression of inflammatory markers were investigated. Suppression of PD-L1 and KRAS led to a slowdown of the cell cycle in the G0/G1 phase and reduced migration, increased sensitivity to chemotherapy and triggered apoptosis of cancer cells. In addition, the conditioned medium of the modulated cells significantly affected the native cancer cells and reduced their viability and drug resistance. Our study suggests that dual silencing of PD-L1 and KRAS by CRISPR/Cas9 may be a promising therapeutic approach for the treatment of lung cancer.  \nKeywords: PD-L1; KRAS; CRISPR; lung; cancer  \n1. Introduction  \nTumors are composed of cancer cells that, together with other cell types, form a rich microenvironment that greatly contributes to tumor progression. Although tumors are able to evade surveillance by the immune system in many ways, the immune system has an essential function in limiting cancer [1] . Immune tolerance is fundamental to the development and spread of cancer and can lead to resistance to immunotherapies. For this reason, the discovery of therapeutic approaches to circumvent these immune resistance pathways in various malignancies is of great interest [2] .  \nIn recent years, promising results have been achieved in cancer immunotherapy using immune checkpoint blockade. Programmed cell death protein 1 (PD-1) and its ligand, the transmembrane protein PD-L1, are responsible for the interaction between T lymphocytes and cancer cells, leading to immune evasion and cancer tolerance. Blocking the PD-1/PD-L1 axis would reactivate the immune response ","cbCaiiGvOxh30PJj","https://ap.wps.com/l/cbCaiiGvOxh30PJj","pdf",2628798,14,"English","# Introduction\n## PD-L1/PD-1 immune checkpoint and cancer immune evasion\n## Limitations of monoclonal antibody immunotherapy\n## Rationale for CRISPR/Cas genetic intervention","[{\"question\":\"How were PD-L1 and KRAS knocked down in lung cancer cells?\",\"answer\":\"The study used the CRISPR/Cas9 system to knock down PD-L1 and KRAS in A549 and H1975 lung adenocarcinoma cells.\"},{\"question\":\"How was PD-L1 knockdown validated experimentally?\",\"answer\":\"PD-L1 knockdown was validated by qPCR and by coculture with lymphocytes.\"},{\"question\":\"What effects did dual PD-L1 and KRAS silencing have on cancer cell behavior?\",\"answer\":\"Dual suppression slowed the cell cycle in G0/G1, reduced migration, increased chemotherapy sensitivity, and triggered apoptosis of cancer cells, with conditioned medium also reducing viability and drug resistance of native cancer cells.\"}]","CRISPR/Cas-Mediated Knockdown of PD-L1 and KRAS in Lung Cancer Cells | PDF",1790033402,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e49d37b7d2165a16875559df837c935.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/45880017350c8ed509977313d9f2d255.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62800e0bee37ba66b5ac92f6d723305e.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6f1eab8d8d8029f9ff8fe19ad8a2ca4b.webp",980,1385]